ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, American Academy of Neurology
6d ago
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease ..read more
Visit website
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, American Academy of Neurology
3w ago
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events ..read more
Visit website
SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, American Academy of Neurology
1M ago
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens ..read more
Visit website
AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, American Academy of Neurology
1M ago
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy ..read more
Visit website
Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, Joseph E. Safdieh, MD, FAAN
2M ago
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders ..read more
Visit website
Cerebral amyloid angiopathy and nontraumatic subdural hemorrhage, AI for neurology boards, weight loss drugs and neurologic conditions
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today
3M ago
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic conditions ..read more
Visit website
Rising incidence of Creutzfeldt-Jakob disease, therapy for prodromal migraine, neurotrauma of blast injury
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, Joseph E. Safdieh, MD, FAAN
3M ago
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the rising incidence of Creutzfeldt-Jakob disease, an effective therapy for prodromal migaine, and neuroinflammation in military personnel exposed to blast injury ..read more
Visit website
DBS and cognition in severe TBI, in utero exposure to antiseizure drugs, best advances of 2023
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, Joseph E. Safdieh, MD, FAAN
4M ago
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and the editorial board’s picks for the best advances of 2023 ..read more
Visit website
Parkinson’s and suicide risk; biomarkers and underrepresentation in Alzheimer’s trials, immune system changes in ALS and Parkinson’s.
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, American Academy of Neurology
4M ago
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson’s patients; underrepresentation of non-White people in Alzheimer’s trial related to biomarker eligibility; early immune systems changes may play early role in ALS and Parkinson's ..read more
Visit website
Serotonin and long COVID, Afib detected 3 years after stroke, Medicare on PET amyloid scans
Neurology Today | Neurology Today Editor’s Picks
by Neurology Today, American Academy of Neurology
5M ago
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare’s decision to cover PET amyloid scans means for neurologists ..read more
Visit website

Follow Neurology Today | Neurology Today Editor’s Picks on FeedSpot

Continue with Google
Continue with Apple
OR